NanoVibronix receives patent for medical imaging navigation overlay

TYLER, Texas - NanoVibronix, Inc. (NASDAQ:NAOV), a medical device company with a current market capitalization of $4.37 million, announced on Monday that its subsidiary ENvue Medical Holdings has been granted U.S. Patent No. 12,402,953 B2 for technology that overlays electromagnetic navigation data onto real-time medical imaging. According to InvestingPro data, the company’s stock has seen significant volatility, falling over 91% year-to-date.

The patent, issued on September 2, 2025, protects the company’s method of integrating navigation with imaging modalities such as X-ray, CT, ultrasound, and MRI in real time. This technology is designed to help clinicians visualize the path of feeding tubes or catheters during placement procedures.

"What sets ENvue apart is our ability to integrate navigation with imaging in real time," said Doron Besser, Chief Executive Officer of NanoVibronix, in a press release statement.

The company indicated that the patented technology aims to increase procedural confidence and reduce the risk of feeding tube misplacement. NanoVibronix also suggested the patent could support potential expansion into vascular navigation applications.

NanoVibronix, headquartered in Tyler, Texas, focuses on two technology platforms: acoustic-based therapeutic devices including PainShield and UroShield, and the ENvue Navigation Platform, which is FDA 510(k) cleared for adult use in feeding tube placement.

The ENvue system provides bedside visualization of tube movement during placement procedures. The company’s navigation platform is currently used for feeding tube placement into the gastrointestinal tract.

NanoVibronix trades on the Nasdaq under the ticker NAOV. InvestingPro subscribers have access to 13 additional investment tips and comprehensive financial metrics for deeper analysis of NAOV’s market position and growth potential.

In other recent news, NanoVibronix, Inc. has announced a 1-for-10 reverse stock split of its common stock, set to take effect on August 11, 2025. This decision follows shareholder approval of a reverse stock split proposal, where the board was authorized to implement a split within a ratio range of 1-for-2 to 1-for-50. Additionally, the company has secured $8 million in funding through an agreement with an institutional investor for the sale of convertible preferred stock, with an initial closing expected around July 21, 2025. NanoVibronix also faced a procedural delay as it adjourned a special meeting due to a lack of quorum, rescheduling it for July 17, 2025. Furthermore, the company corrected a typographical error in the floor price of its Series G Preferred Stock, adjusting it from $1.02 to $1.91. These developments reflect ongoing adjustments and strategic financial actions by NanoVibronix.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.